Significant Ownership of Fairmount Funds Management LLC

Signature - Title
/s/ Peter Harwin - Peter Harwin, Managing Member
Location
West Conshohocken, PA
Summary
This page shows a list of all the recent SCHEDULE 13D/G filings made by Fairmount Funds Management LLC.

Notify me when Fairmount Funds Management LLC files a new Schedule 13D/G report.

⭐ Subscribe ⭐

Significant Ownership of Fairmount Funds Management LLC

Sym Company Class Ownership Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
GLTO Galecto, Inc. Common Stock, par value $0.00001 per share 20% $190,117,660 +$181,455,120 8,713,000 +2095% Fairmount Funds Management LLC 09 Feb 2026
ORKA ORUKA THERAPEUTICS, INC. Common Stock, $0.001 par value 20% $161,971,372 +$38,464,806 11,162,741 +31% Fairmount Funds Management LLC 17 Sep 2025
JBIO Jade Biosciences, Inc. Common Stock, $0.0001 par value 20% $89,373,614 +$26,797,898 10,353,875 +43% Fairmount Funds Management LLC 06 Oct 2025
CBIO Crescent Biopharma, Inc. Ordinary Shares, $0.001 par value 19% $73,252,396 +$32,700,021 5,643,482 +81% Fairmount Funds Management LLC 04 Dec 2025
VRDN Viridian Therapeutics, Inc.\DE Common Stock, $0.01 par value 15% $345,826,621 16,025,330 Fairmount Funds Management LLC 23 Oct 2025
APGE Apogee Therapeutics, Inc. Common Stock, $0.00001 par value 10% $456,430,807 +$20,390,674 6,047,027 +4.7% Peter Evan Harwin 22 Jan 2026
SYRE SPYRE THERAPEUTICS, INC. Common Stock, $0.0001 par value 10% $136,033,480 8,106,882 Peter Evan Harwin 15 Oct 2025
COGT Cogent Biosciences, Inc. Common Stock, $0.001 par value 9.9% $577,623,327 +$13,657,440 16,261,918 +2.4% Fairmount Funds Management LLC 22 Jan 2026
IKT Inhibikase Therapeutics, Inc. Common Stock, par value $0.001 per share 9.9% $15,861,980 7,018,575 Fairmount Funds Management LLC 31 Dec 2024
ELVN ENLIVEN THERAPEUTICS, INC. Common Stock, par value $0.001 per share 6.3% $83,321,918 +$11,419,103 3,711,444 +16% Fairmount Funds Management LLC 30 Jun 2025
DNTH DIANTHUS THERAPEUTICS, INC. Common Stock, $0.001 par value 4.9% $72,191,285 -$64,524,950 2,139,635 -47% Fairmount Funds Management LLC 21 Nov 2025
ATXS Astria Therapeutics, Inc. Common Stock, par value $0.001 per share 4% $17,304,917 -$25,421,673 2,377,049 -59% Fairmount Funds Management LLC 14 Oct 2025
KNSA Kiniksa Pharmaceuticals International, plc Class A Ordinary Shares, nominal value $0.000273235 per share 0% $0 0 Fairmount Funds Management LLC 31 Dec 2024
ANAB ANAPTYSBIO, INC. Common Stock, par value $0.001 per share 0% $0 -$34,599,719 0 -100% Fairmount Funds Management LLC 31 Dec 2024

Schedules 13D/G Reported by Fairmount Funds Management LLC:

Sym Target Class Ownership Change Current Shares Change Value Reporting name Form Report Period Filing Date
* An asterisk sign (*) next to the price indicates that the price is likely invalid.